

MEMORANDUM

TO: Reporters and Editors
FR: Jill Kozeny, for Sen. Grassley, 202/224-1308
Wendy Carey, for Sen. Baucus, 202/224-6769
RE: FDA, Cyberonics
DA: Friday, July 15, 2005

Senate Finance Committee Chairman Chuck Grassley and Ranking Member Max Baucus issued the following comment this afternoon.

"The Finance Committee will continue its inquiry into the Food and Drug Administration's consideration of the pre-market approval supplement for the vagus nerve stimulator to be used for depression that is treatment-resistant. Both the effectiveness and the safety of medical devices must be ensured prior to their approval by the Food and Drug Administration."